Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

[1]  P. Feuerstadt,et al.  Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis , 2022, Antimicrobial Stewardship and Healthcare Epidemiology.

[2]  D. Gerding,et al.  Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial , 2022, BMC Infectious Diseases.

[3]  W. Nelson,et al.  Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. , 2022, Journal of the American Medical Directors Association.

[4]  J. Wortman,et al.  SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. , 2022, The New England journal of medicine.

[5]  S. Khanna,et al.  Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection , 2021, Digestive Diseases and Sciences.

[6]  K. Garey,et al.  Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  C. Kelly,et al.  ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections , 2021, The American journal of gastroenterology.

[8]  D. Pardi,et al.  Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. , 2021, Gastroenterology.

[9]  D. Gerding,et al.  Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. , 2020, The New England journal of medicine.

[10]  Miriam H. Huntley,et al.  Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. , 2019, The New England journal of medicine.

[11]  D. Gerding,et al.  Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Pardi,et al.  Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  P. Ravaud,et al.  Methods and Reporting Studies Assessing Fecal Microbiota Transplantation , 2017, Annals of Internal Medicine.

[15]  E. Dubberke,et al.  Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Colville,et al.  Adverse events in faecal microbiota transplant: a review of the literature. , 2016, The Journal of hospital infection.

[17]  J. Bakken,et al.  Treating Clostridium difficile infection with fecal microbiota transplantation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.